fluoroquinolone

From Aaushi
Jump to navigation Jump to search

Indications

* serious side effects generally outweigh the benefits for patients with sinusitis, bronchitis, & uncomplicated urinary tract infections[17]

Contraindications

Antimicrobial activity

Adverse effects

Drug interactions

Mechanism of action

More general terms

More specific terms

References

  1. 1.0 1.1 Medical Knowledge Self Assessment Program (MKSAP) 11, 19. American College of Physicians, Philadelphia 1998, 2021
  2. 2.0 2.1 Prescriber's Letter 9(11):64 2002
  3. 3.0 3.1 Medications Can Cause Seizures Prescriber's Letter 10(3):16 2003 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=190320&pb=PRL (subscription needed) http://www.prescribersletter.com
  4. 4.0 4.1 4.2 Prescriber's Letter 10(7):40 2003
  5. 5.0 5.1 5.2 Journal Watch 23(19):152, 2003 van der Linden PD et al, Arch Intern Med 163:1801, 2003
  6. 6.0 6.1 6.2 Prescriber's Letter 11(5):29 2004 Use of Fluoroquinolone antibiotics in Children Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=200506&pb=PRL (subscription needed) http://www.prescribersletter.com
  7. Prescriber's Letter 11(9): 2004 Summary of Commonly Used Fluoroquinolones Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=200906&pb=PRL (subscription needed) http://www.prescribersletter.com
  8. 8.0 8.1 8.2 8.3 Etminan M e al Oral Fluoroquinolones and the Risk of Retinal Detachment JAMA. 2012;307(13):1414-1419 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22474205 <Internet> http://jama.ama-assn.org/content/307/13/1414.short
  9. 9.0 9.1 Bird ST et al. Risk of acute kidney injury associated with the use of fluoroquinolones. CMAJ 2013 Jul 9; 185:E475 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23734036 <Internet> http://www.cmaj.ca/content/185/10/E475?ijkey=719ce2e015f88fb295f33da8cfe395060fb60430&keytype2=tf_ipsecsha
  10. 10.0 10.1 FDA MedWatch. August 15, 2013 Fluoroquinolone Antibacterial Drugs: Drug Safety Communication- Risk for possibly permanent nerve damage. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm365302.htm
  11. Chou HW et al Risk of Severe Dysglycemia Among Diabetic Patients Receiving Levofloxacin, Ciprofloxacin, or Moxifloxacin in Taiwan. Clin Infect Dis. August 14, 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23948133 <Internet> http://cid.oxfordjournals.org/content/early/2013/07/23/cid.cit439.abstract
  12. 12.0 12.1 Prescriber's Letter 20(10): 2013 Adverse Reactions with Systemic Quinolones Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=291004&pb=PRL (subscription needed) http://www.prescribersletter.com
  13. 13.0 13.1 Pasternak B et al Association Between Oral Fluoroquinolone Use and Retinal Detachment. JAMA. 2013;310(20):2184-2190. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24281462 <Internet> http://jama.jamanetwork.com/article.aspx?articleid=1785461
    Brett AS Oral Fluoroquinolone Use and Retinal Detachment Reconciling Conflicting Findings in Observational Research. JAMA. 2013;310(20):2151-2153 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24281459 <Internet> http://jama.jamanetwork.com/article.aspx?articleid=1785435
  14. 14.0 14.1 Etminan M et al. Oral fluoroquinolone use and risk of peripheral neuropathy: A pharmacoepidemiologic study. Neurology 2014 Aug 22 PMID: https://www.ncbi.nlm.nih.gov/pubmed/25150290
  15. 15.0 15.1 Inghammar M et al Oral fluoroquinolone use and serious arrhythmia: bi-national cohort study. BMJ 2016;352:i843 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26920666 <Internet> http://www.bmj.com/content/352/bmj.i843
  16. Raguideau F et al. Association between oral fluoroquinolone use and retinal detachment. JAMA Ophthalmol 2016 Apr; 134:415 PMID: https://www.ncbi.nlm.nih.gov/pubmed/26967005
  17. 17.0 17.1 FDA Safety Watch. May 12, 2016 Fluoroquinolone Antibacterial Drugs: Drug Safety Communication
    FDA Advises Restricting Use for Certain Uncomplicated Infections. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm500665.htm
    FDA Drug Safety Communication. May 12, 2016 FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together http://www.fda.gov/Drugs/DrugSafety/ucm500143.htm
  18. 18.0 18.1 18.2 18.3 FDA Safety Communication. July 26, 2016 Fluoroquinolone Antibacterial Drugs for Systemic Use: Drug Safety Communication - Warnings Updated Due to Disabling Side Effects. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm513065.htm
  19. 19.0 19.1 Muanda FT, Sheehy O, Berard A Use of antibiotics during pregnancy and risk of spontaneous abortion. CMAJ 2017 May 1;189:E625-33 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28461374 <Internet> http://www.cmaj.ca/content/189/17/E625.full.pdf+html
  20. 20.0 20.1 20.2 Brooks M FDA: Fluoroquinolones Not Linked to Retinal Detachment Medscape - May 11, 2017 http://www.medscape.com/viewarticle/879889
    FDA Drug Safety Communication. May 12, 2017 FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. https://www.fda.gov/Drugs/DrugSafety/ucm511530.htm
  21. 21.0 21.1 Lowes R FDA Approves Delafloxacin (Baxdela) for Skin Infections Medscape - Jun 19, 2017. http://www.medscape.com/viewarticle/881827
  22. 22.0 22.1 Sodhi M, Sheldon CA, Carleton B, Etminan M. Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome: Nested case-control study. Neurology 2017 Jul 28 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28754842 <Internet> http://www.neurology.org/content/89/8/792
  23. 23.0 23.1 Cheng JZ, Sodhi M, Etminan M, Carleton BC. Fluoroquinolone Use and Risk of Carpal Tunnel Syndrome: A Pharmacoepidemiologic Study. Clin Infect Dis. 2017 Apr 24. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28444196
  24. 24.0 24.1 Farid S, Mahmood M, Abu Saleh OM et al. Clinical manifestations and outcomes of fluoroquinolone- related acute interstitial nephritis. Mayo Clin Proc. 2018 Jan;93(1):25-31 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29157532 <Internet> http://www.mayoclinicproceedings.org/article/S0025-6196(17)30695-X/fulltext
  25. 25.0 25.1 Pasternak B et al. Fluoroquinolone use and risk of aortic aneurysm and dissection: Nationwide cohort study. BMJ 2018 Mar 8; 360:k678. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29519881 Free PMC Article
    Juurlink DN. Fluoroquinolones and the aorta: Possible link with aortic pathology but the absolute risk appears very low. BMJ 2018 Mar 8; 360:k988. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29519782
  26. 26.0 26.1 26.2 FDA Safety Alert. July 10, 2018 Fluoroquinolone Antibiotics: FDA Requires Labeling Changes Due to Low Blood Sugar Levels and Mental Health Side Effects. https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm612979.htm
    FDA News Release, July 10, 2018 FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm612995.htm
  27. 27.0 27.1 Walker M FDA Warns on Aortic Aneurysms With Fluoroquinolones. Adds to already long list of issues with popular antibiotic class. MedPage Today. Dec 20, 2018 https://www.medpagetoday.com/publichealthpolicy/fdageneral/77060
    FDA Safety Alert. Dec 20, 2018 Fluoroquinolone Antibiotics: Safety Communication - Increased Risk of Ruptures or Tears in the Aorta Blood Vessel in Certain Patients. https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm628960.htm
  28. Lewis T, Cook J. Fluoroquinolones and tendinopathy: a guide for athletes and sports clinicians and a systematic review of the literature. J Athl Train. 2014 May-Jun;49(3):422-7. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24762232 Free PMC Article
  29. 29.0 29.1 29.2 Morales D, Pacurariu A, Slattery J et al. Association between peripheral neuropathy and exposure to oral fluoroquinolone or amoxicillin-clavulanate therapy. JAMA Neurol 2019 Jul; 76:827 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31034074 https://jamanetwork.com/journals/jamaneurology/fullarticle/2731583
  30. 30.0 30.1 Gopalakrishnan C et al. Association of fluoroquinolones with the risk of aortic aneurysm or aortic dissection. JAMA Intern Med 2020 Sep 8; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/32897307 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2770379
    Dong Y-H et al. Association of infections and use of fluoroquinolones with the risk of aortic aneurysm or aortic dissection. JAMA Intern Med 2020 Sep 8; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32897358 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2770378
  31. 31.0 31.1 Newton ER, Akerman AW, Strassle PD et al Association of Fluoroquinolone Use With Short-term Risk of Development of Aortic Aneurysm. JAMA Surg. Published online January 6, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33404647 https://jamanetwork.com/journals/jamasurgery/fullarticle/2774747
  32. 32.0 32.1 Shah S et al. In-class cross-reactivity among hospitalized patients with hypersensitivity reactions to fluoroquinolones. Antimicrob Agents Chemother 2023 May 8; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37154772 https://journals.asm.org/doi/10.1128/aac.00374-23
    Adams KK, Shah S. Health system evaluation of fluoroquinolone hypersensitivity: An assessment of cross-reactivity. J Antimicrob Chemother 2023 May 10; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/37161664 https://academic.oup.com/jac/advance-article-abstract/doi/10.1093/jac/dkad136/7158810